Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

8-OH-DPAT

Catalog No: tcsc0043224

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
78950-78-4

Formula:
$C_{16}H_{25}NO$

Pathway:
Neuronal Signaling;GPCR/G Protein

Target:
5-HT Receptor;5-HT Receptor

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 155 mg/mL (626.57 mM)

Alternative Names:
8-Hydroxy-DPAT

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
247.38

Product Description

8-OH-DPAT is a potent and selective **5-HT** agonist, with a **pIC_{50}** of 8.19 for 5-HT1A and a **K_i** of 466 nM for 5-HT7; 8-OH-DPAT weakly binds to 5-HT1B (pIC_{50}, 5.42), 5-HT (pIC_{50}
IC50 & Target: pIC50: 8.19 (5-HT1A)[1]

Ki: 466 nM (5-HT7)[2]

In Vitro: 8-OH-DPAT is a potent and selective 5-HT agonist, with a pIC_{50} of 8.19 for 5-HT1A; weakly binds to 5-HT1B (pIC_{50}, 5.42), 5-HT (pIC_{50}[1]. 8-OH-DPAT has high affinity at 5-HT7 with a K_i of 466 nM, and does not bind to 5-HT6 or 5-HT4[2].

In Vivo: 8-OH-DPAT (1 mg/kg) normalizes hypolocomotion, significantly increases wakefulness and reduces the duration of REM sleep without effect on the duration of non-REM sleep in the dark period in orexin knockout (KO) mice. 8-OH-DPAT shows no obvious effect on wakefulness or the duration of either REM sleep or non-REM sleep in WT mice. 8-OH-DPAT (1 mg/kg, s.c.) activates 5-HT1A receptor in orexin knockout mice[3].